T1	Participants 108 228	patients with acute myeloid leukemia and myelodysplastic syndromes: a Japanese multicenter randomized, controlled study.
T2	Participants 288 489	prophylactic effects of capsule forms of fluconazole (n = 110) and itraconazole (n = 108) in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) during and after chemotherapy.
T3	Participants 713 730	patients with MDS
T4	Participants 1007 1056	patients with neutrophil counts of >0.1 x 10(9)/L
T5	Participants 1301 1351	patients with AML or MDS who received chemotherapy
